✦ LIBER ✦

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial

✍ Scribed by Olivier F. Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence Title; Vladimir Dzavik; Madhu Natarajan; Juan Angel; Nuria Batalla; Natalie Alméras; Olivier Costerousse; Robert De Larochellière; Louis Roy; Jean-Pierre Després

Book ID: 117579944
Publisher: Pulsus Group Inc
Year: 2009
Tongue: English
Weight: 803 KB
Volume: 25
Category: Article
ISSN: 0828-282X
DOI: 10.1016/s0828-282x(09)70136-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II—study design and rationale

✍ Rajendra H. Mehta; John H. Alexander; Robert Emery; Stephen J. Ellis; Vic Hassel 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 209 KB

Rationale, design and baseline character

Rationale, design and baseline characteristics of the PRO-TECT II study: PROpofol CardioproTECTion for Type II diabetics: A randomized, controlled trial of high-dose propofol versus isoflurane preconditioning in patients undergoing on-pump coronary artery bypass graft surgery

✍ David M. Ansley; Koen Raedschelders; David D.Y. Chen; Peter T. Choi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 249 KB